Luis Borges - Metagenomi, Common Chief Officer
| MGX Stock | 2.02 0.01 0.50% |
Executive
Luis Borges is Chief Officer of Metagenomi, Common Stock
| Age | 62 |
| Address | 5959 Horton Street, EmeryVille, CA, United States, 94608 |
| Phone | 510 871 4880 |
| Web | https://www.metagenomi.co |
Luis Borges Latest Insider Activity
Tracking and analyzing the buying and selling activities of Luis Borges against Metagenomi, Common stock is an integral part of due diligence when investing in Metagenomi, Common. Luis Borges insider activity provides valuable insight into whether Metagenomi, Common is net buyers or sellers over its current business cycle. Note, Metagenomi, Common insiders must abide by specific rules, including filing SEC forms every time they buy or sell Metagenomi, Common'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Luis Borges over a month ago Disposition of 7452 shares by Luis Borges of Century Therapeutics at 1.03 subject to Rule 16b-3 | ||
Luis Borges over a year ago Exercise or conversion by Luis Borges of 7452 shares of Century Therapeutics subject to Rule 16b-3 | ||
Luis Borges over a year ago Exercise or conversion by Luis Borges of 63616 shares of Century Therapeutics subject to Rule 16b-3 | ||
Luis Borges over a year ago Acquisition by Luis Borges of 21875 shares of Century Therapeutics subject to Rule 16b-3 |
Metagenomi, Common Management Efficiency
The company has Return on Asset of (0.1392) % which means that on every $100 spent on assets, it lost $0.1392. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2898) %, meaning that it generated no profit with money invested by stockholders. Metagenomi, Common's management efficiency ratios could be used to measure how well Metagenomi, Common manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.64 in 2024, whereas Return On Tangible Assets are likely to drop (0.20) in 2024. At this time, Metagenomi, Common's Debt To Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 0.72 in 2024, whereas Total Assets are likely to drop slightly above 337.8 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Zi Lim | Kulicke and Soffa | 36 | |
| KeJuan Wilkins | Nike Inc | N/A | |
| Gregory Meunier | HNI Corp | 53 | |
| William Billings | Globalfoundries | 47 | |
| Nancy Kelly | Globalfoundries | N/A | |
| Nicole Graham | Nike Inc | N/A | |
| Yun Lee | Franklin Wireless Corp | 63 | |
| Pete Calichman | Skechers USA | N/A | |
| Eunice Han | Skechers USA | N/A | |
| Kourtney Smith | HNI Corp | 54 | |
| Vincent II | HNI Corp | 51 | |
| Sam Franklin | Globalfoundries | N/A | |
| Muge Dogan | Nike Inc | N/A | |
| John CPA | Globalfoundries | 54 | |
| Greg Pedersen | Globalfoundries | N/A | |
| Mun Wong | Kulicke and Soffa | 63 | |
| Theodore JD | MagnaChip Semiconductor | 54 | |
| Michael Roch | HNI Corp | 45 | |
| Matthew CFA | HNI Corp | N/A | |
| Brad Clay | Globalfoundries | N/A | |
| Lisa Lim | Kulicke and Soffa | N/A | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.14 |
Metagenomi, Common Stock Leadership Team
Elected by the shareholders, the Metagenomi, Common's board of directors comprises two types of representatives: Metagenomi, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Metagenomi,. The board's role is to monitor Metagenomi, Common's management team and ensure that shareholders' interests are well served. Metagenomi, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Metagenomi, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Thomas, CEO CoFounder | ||
| Jian MBA, COO President | ||
| Pamela MBA, Chief Officer | ||
| Joseph MD, CoFounder Board | ||
| Simon MSc, Chief Relations | ||
| Luis Borges, Chief Officer | ||
| Matthew JD, Compliance Legal | ||
| Christopher Brown, Head Discovery | ||
| Jak MD, CoFounder Board | ||
| Alan Brooks, Senior Preclinical | ||
| Simren LLM, Vice Legal |
Metagenomi, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Metagenomi, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (1.34) % | ||||
| Operating Margin | (0.84) % | ||||
| Current Valuation | (150.92 M) | ||||
| Shares Outstanding | 37.43 M | ||||
| Shares Owned By Insiders | 33.47 % | ||||
| Shares Owned By Institutions | 36.07 % | ||||
| Number Of Shares Shorted | 443.56 K | ||||
| Price To Book | 0.38 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Metagenomi, Stock Analysis
When running Metagenomi, Common's price analysis, check to measure Metagenomi, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Metagenomi, Common is operating at the current time. Most of Metagenomi, Common's value examination focuses on studying past and present price action to predict the probability of Metagenomi, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Metagenomi, Common's price. Additionally, you may evaluate how the addition of Metagenomi, Common to your portfolios can decrease your overall portfolio volatility.